Advanced Solutions in Regenerative Medicine
We harness regenerative medicine to develop disease-modifying, chondroprotective technologies for combatting osteoarthritis and related pathologies.
At Cartilago, we harness regenerative medicine to develop disease-modifying, chondroprotective technologies for combatting osteoarthritis and related pathologies. We directly target underlying disease pathology to offer not just symptomatic relief, but also to inhibit the typical natural progression of the disease. Our technologies are being adapted to address additional indications, including for anti-aging solutions, wound care and anti-metastatic therapies in cancer.
We are passionate about science, and what it can do for wellness and health.
The past several decades have seen a substantial increase in the incidence of pain and morbidity associated with idiopathic osteoarthritis of the knee and hip joints. Analgesics and non-steroidal anti-inflammatory drugs are currently extensively used as non-surgical treatment options, but they only act as palliative symptomatic treatments. They are not disease-modifying, do not offer a cure, and have been associated with an increased risk for adverse events.
CARTILAGO’S DISEASE-MODIFYING TECHNOLOGIES ARE CENTERED UPON PEPTIDYL DERIVATIVES THAT DISPLAY EXTRAORDINARY POTENCY IN STIMULATING THE PRODUCTION OF NEW CARTILAGE TISSUE, AS WELL AS THE GENERATION OF EXTRACELLULAR MATRIX AND COLLAGEN, AND THE ENDOGENOUS PRODUCTION OF HYALURONIC ACID.
In preclinical studies, they:
- Stimulate endogenous production of cartilage and new tissue;
- Ease pathological joint states characterized by chronic pain;
- Act to repair and regenerate the extracellular matrix and aged tissues;
- Stimulate tissue regeneration without the need for invasive external interventions;
- Act not transiently but long term.
Clinical trial will start soon. For more information, contact us.